International Journal of Modern and Alternative Medicine Research
ISSN: 2053-1834
Vol. 6(2), pp. 17-23, April 2018

Febuxostat for the treatment of hyperuricemia in elderly patients with chronic kidney disease: A retrospective study

Ai Yu Yang*

Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.

*To whom correspondence should be addressed. E-mail:

Received 13 March, 2018; Received in revised form 08 April, 2018; Accepted 12 April, 2018.


Febuxostat, Hyperuricemia, Renal insufficiency, Chronic.

Achieving the recommended serum uric acid (sUA) concentration of <6.0 mg/dl is difficult in elderly patients (65 years of age or older) with chronic kidney disease. The xanthine oxidase inhibitor febuxostat has been used for treatment of this patient group, but its efficacy and safety remain unclear. In this retrospective cohort study, we recorded changes in sUA, rates of target sUA achievement (<6.0 mg/dl), changes in estimated glomerular filtration rate (eGFR), and adverse events in 123 elderly patients (mean age 76.6 ± 7.2 years, 84 males and 39 females) with hyperuricemia and severe CKD (eGFR< 30 ml/min/1.73 m2) treated using febuxostat at Kaohsiung Medical University Hospital from January 2015 to December 2015. Febuxostat significantly lowered mean sUA from 9.5 ± 1.9 versus 5.4 ± 2.1 mg/dl after 12 weeks of treatment (P<0.001), and 60.2% achieved the target sUA of <6 mg/dl. There were no significant changes in eGFR (19.1 ± 6.9 versus 19.6 ± 8.4, P=0.233) or indices of liver dysfunction. Only two patients exhibited adverse events, suspected febuxostat allergy (skin rash and itching) and epigastric pain in one patient each. Febuxostat effectively lowers sUA levels in elderly patients with CKD without severe adverse events.

2018 BluePen Journals Ltd.

© 2013-2019 - BluePen Journals | Terms | Privacy policy | Advert | Help |